Thus, selective PDGFRβ drug targeting allows the delivery of compounds to inhibit ROCK-mediated HSC contraction during cirrhosis, as shown by the decreased hepatic p-moesin and p-MLC in Y27pPBHSA-treated rats. Here, MLC1 is linked to Cirrhosis.